 |
|
Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
April 27, 2009SAN DIEGO - Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered a new drug combination that significantly hinders tumor growth in neuroblastoma, a childhood cancer. The study was presented today at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology (ASPHO).
By combining a novel multi-kinase inhibitor, vandetanib, with 13-cis-retinoic acid (CRA), a drug often used for severe acne, researchers from the Children's Cancer Hospital at M. D. Anderson found that the two therapies reduced neuroblastoma tumors by 86 percent in pre-clinical tests.
Peter Zage, M.D., Ph.D., who specializes in neuroblastoma at the Children's Cancer Hospital, received this year's Young Investigator Award from ASPHO and was selected to present his research today in a special platform session.
"By itself, vandetanib inhibited tumor growth by two-thirds and decreased blood vessel formation around neuroblastoma tumors in mice," says Zage. "When combined with CRA, the impact was even greater on tumor growth."
Vandetanib blocks a family of endothelial growth factors and receptors that promote tumor growth as well as the RET oncogene, which can signal neuroendocrine cells to develop into neuroblastoma cells. Although commonly used in treatment for neuroblastoma, CRA by itself does not have a significant impact against the childhood cancer. However, it works in combination therapy to differentiate neuroblastoma cells into mature benign neural cells.
Currently, there is a Phase I clinical trial open for children with multiple-relapsed neuroblastoma to further study the new therapy combination. This trial is the first in the world to test vandetanib in children.
Zage says in addition to the pediatric patients enrolled in the Phase I trial, adult patients with lung cancer have received vandetanib and have tolerated the novel drug well.
According to the American Cancer Society, approximately 650 children, mainly under the age of five, are diagnosed with neuroblastoma in the United States each year. Close to two-thirds of these children are diagnosed after the cancer has metastasized to other parts of the body. For these patients with high-risk neuroblastoma, long-term survival is less than 40 percent because the tumors are often resistant to traditional chemotherapy.
University of Texas M. D. Anderson Cancer Center
"By itself, vandetanib inhibited tumor growth by two-thirds and decreased blood vessel formation around neuroblastoma tumors in mice," says Zage. "When combined with CRA, the impact was even greater on tumor growth."
Vandetanib blocks a family of endothelial growth factors and receptors that promote tumor growth as well as the RET oncogene, which can signal neuroendocrine cells to develop into neuroblastoma cells. Although commonly used in treatment for neuroblastoma, CRA by itself does not have a significant impact against the childhood cancer. However, it works in combination therapy to differentiate neuroblastoma cells into mature benign neural cells.
Currently, there is a Phase I clinical trial open for children with multiple-relapsed neuroblastoma to further study the new therapy combination. This trial is the first in the world to test vandetanib in children.
Zage says in addition to the pediatric patients enrolled in the Phase I trial, adult patients with lung cancer have received vandetanib and have tolerated the novel drug well.
According to the American Cancer Society, approximately 650 children, mainly under the age of five, are diagnosed with neuroblastoma in the United States each year. Close to two-thirds of these children are diagnosed after the cancer has metastasized to other parts of the body. For these patients with high-risk neuroblastoma, long-term survival is less than 40 percent because the tumors are often resistant to traditional chemotherapy.
University of Texas M. D. Anderson Cancer Center
Neuroblastoma Current Events and Neuroblastoma News RSSWeizmann Institute Scientists Discover A New Protein Partnership That Leads to Pediatric Tumor Regression
Why are some pediatric cancers able to spontaneously regress? Prof. Michael Fainzilber and his team of the Weizmann Institute's Biological Chemistry Department seem to have unexpectedly found part of the answer.
PET Can Help Guide Treatment Decisions for a Common Pediatric Cancer
A new study published in the August issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) is an important tool for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease.
Protein That Promotes Cancer Cell Growth Identified
Scientists at Burnham Institute for Medical Research (Burnham) have found that the Caspase-8 protein, long known to play a major role in promoting programmed cell death (apoptosis), helps relay signals that can cause cancer cells to proliferate, migrate and invade surrounding tissues.
U of M Researchers Find Childhood Cancer Risk Rises with Mother's Age
Research from the Masonic Cancer Center, University of Minnesota indicates that a baby born to an older mother may have a slightly increased risk for many of the cancers that occur during childhood.
Variations in 5 genes raise risk for most common brain tumors
Common genetic variations spread across five genes raise a person's risk of developing the most frequent type of brain tumor, an international research team reports online in Nature Genetics.
Genetic finding could lead to targeted therapy for neuroblastoma
Researchers have identified a genetic glitch that could lead to development of neuroblastoma, a deadly form of cancer that typically strikes children under 2.
Researchers identify gene that regulates tumors in neuroblastoma
Virginia Commonwealth University researchers have identified a gene that may play a key role in regulating tumor progression in neuroblastoma, a form of cancer usually found in young children.
New therapy enlists immune system to boost cure rate in a childhood cancer
A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.
Immunotherapy effective against neuroblastoma in children
A phase III study has shown that adding an antibody-based therapy that harnesses the body's immune system resulted in a 20 percent increase in the number of children living disease-free for at least two years with neuroblastoma.
Drug inhibits neuroblastoma blood supply in pre-clinical tests
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found a way to prevent blood vessels from aiding the growth of neuroblastoma, a childhood cancer.
More Neuroblastoma Current Events and Neuroblastoma News Articles
 |
Neuroblastoma by Nai-Kong V. Cheung (Editor), Susan L. Cohn (Editor) Neuroblastoma is a medical enigma. As a childhood neoplasm arising from neural crest cells, it is characterized by diverse clinical behaviors ranging from spontaneous remission to rapid tumor progression and death. Although clinical outcome can be predicted to a large extent by the stage of disease and the age at diagnosis, an in-depth understanding of its clinico-pathological behavior, now greatly aided by sophisticated molecular genetic profiling, will improve diagnostic precision and refine risk-based therapies. Comprehensive international efforts have advanced our understanding of tumor biology, and improved the clinical management of children with neuroblastoma. This book reviews our current understanding of the genes and biological pathways that contribute to neuroblastoma... |
 |
Fight Against Neuroblastoma Sweatshirt X-Large White by Shop Zeus |
 |
Cure Neuroblastoma Keychain by Design a Product LLC Text on keychain: Cure Neuroblastoma * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
![Neuroblastoma Injected By Viral Oestogena [Explicit]](http://ecx.images-amazon.com/images/I/41anx1tCcwL._SL160_.jpg) |
Neuroblastoma Injected By Viral Oestogena [Explicit] Thorwald / Pulmonary Fibrosis (Primary Contributor) |
 |
Neuroblastoma Awareness Ribbon Mouse Pad by MyHeritageWear.com The Neuroblastoma Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Neuroblastoma Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Neuroblastoma Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Neuroblastoma by Velvet Acid Christ |
 |
Neuroblastoma Research Trends by Lucas H. Andre (Editor), Nathan E. Roux (Editor) Neuroblastoma is a cancer that develops from nerve cells found in several areas of the body. Neuroblastoma most commonly affects children age 5 or younger, though it may rarely occur in older children and adults. Neuroblastoma is the most common cancer in babies. Neuroblastoma develops in tissue that makes up the sympathetic nervous system - the system of nerves that automatically regulates your heart rate, blood pressure and digestion. Neuroblastoma most commonly arises in and around the adrenal glands, which sit atop the kidneys. However, neuroblastoma can also develop in other areas of the abdomen and in the chest, neck and pelvis. This book presents important new research in this field of research. |
 |
Cure Neuroblastoma Long Sleeve T-shirt Large White by Shop Zeus |
 |
Neuroblastoma: Tumor Biology and Therapy by Carl E. Pochedly (Author) The purpose of this book is to provide a comprehensive review of current knowledge and to give a thoughtful assessment of the many complex issues involved in the diagnosis and treatment of this common malignant solid tumor found in children. This up-to-date publication also reviews new concepts in histogenesis and histopathology of neuroblastoma. Divided into three main sections, this work focuses on tumor biology, clinical management, and prognosis and future perspectives. This fascinating work includes in-depth discussions on neuroblastoma in infancy and the manifestations of this tumor as it affects various organs and various parts of the body. It also provides guidelines for treatment with surgery, radiotherapy and chemotherapy. This ideal resource is loaded with information for all... |
 |
The Epidemiology of Neuroblastoma by Stefano Parodi (Author), Riccardo Haupt (Author) Neuroblastoma is a cancer of the sympathetic nervous system. It is the most common tumor in the first year of life and the most common solid extra-cranial cancer in childhood. Neuroblastoma represents an enigmatic disease, in that some cases, especially in infants, tend to spontaneously regress, even in advanced states, while many patients are refractary to any therapeutical approach and show an inexorable clinical course. As most of the other solid cancers in children, the distribution of Neuroblastoma risk worldwide is only partly known. In Western countries, its incidence varies between 7 and 16 cases per million children and it tends to decrease increasing the age.Besides, survival of patients affected by such disease, in relation with clinical and biological characteristics, have... |
| © 2009 BrightSurf.com |